 | • レポートコード：GIR-107A14458 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、83ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、鎌状赤血球症治療薬関連血管閉塞症のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。鎌状赤血球症治療薬関連血管閉塞症の種類別市場規模（SGD-2083、クリザンリズマブ、PF-04447943、NVX-508、その他）、用途別市場規模（クリニック、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・鎌状赤血球症治療薬関連血管閉塞症の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca Plc、Bristol-Myers Squibb Company、Gilead Sciences Inc、Modus Therapeutics Holding AB、Novartis AG、NuvOx Pharma LLC、Pfizer Inc、Seattle Genetics Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：SGD-2083、クリザンリズマブ、PF-04447943、NVX-508、その他 ・用途別分析2016年-2026年：クリニック、病院、その他 ・鎌状赤血球症治療薬関連血管閉塞症の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・鎌状赤血球症治療薬関連血管閉塞症のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・鎌状赤血球症治療薬関連血管閉塞症のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・鎌状赤血球症治療薬関連血管閉塞症の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・鎌状赤血球症治療薬関連血管閉塞症の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
SGD-2083
Crizanlizumab
PF-04447943
NVX-508
Others
Market segment by Application, can be divided into
Clinic
Hospital
Others
Market segment by players, this report covers
AstraZeneca Plc
Bristol-Myers Squibb Company
Gilead Sciences Inc
Modus Therapeutics Holding AB
Novartis AG
NuvOx Pharma LLC
Pfizer Inc
Seattle Genetics Inc
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, with revenue, gross margin and global market share of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug from 2019 to 2021.
Chapter 3, the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug
1.2 Classification of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Type
1.2.1 Overview: Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type in 2020
1.2.3 SGD-2083
1.2.4 Crizanlizumab
1.2.5 PF-04447943
1.2.6 NVX-508
1.2.7 Others
1.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Application
1.3.1 Overview: Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size & Forecast
1.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast by Region
1.5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region, (2016-2021)
1.5.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Prospect (2016-2026)
1.5.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Prospect (2016-2026)
1.5.6 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
1.6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
1.6.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Trends Analysis
2 Company Profiles
2.1 AstraZeneca Plc
2.1.1 AstraZeneca Plc Details
2.1.2 AstraZeneca Plc Major Business
2.1.3 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.1.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Plc Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.2.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 Gilead Sciences Inc
2.3.1 Gilead Sciences Inc Details
2.3.2 Gilead Sciences Inc Major Business
2.3.3 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.3.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Gilead Sciences Inc Recent Developments and Future Plans
2.4 Modus Therapeutics Holding AB
2.4.1 Modus Therapeutics Holding AB Details
2.4.2 Modus Therapeutics Holding AB Major Business
2.4.3 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.4.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Modus Therapeutics Holding AB Recent Developments and Future Plans
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.5.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Novartis AG Recent Developments and Future Plans
2.6 NuvOx Pharma LLC
2.6.1 NuvOx Pharma LLC Details
2.6.2 NuvOx Pharma LLC Major Business
2.6.3 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.6.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 NuvOx Pharma LLC Recent Developments and Future Plans
2.7 Pfizer Inc
2.7.1 Pfizer Inc Details
2.7.2 Pfizer Inc Major Business
2.7.3 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.7.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Inc Recent Developments and Future Plans
2.8 Seattle Genetics Inc
2.8.1 Seattle Genetics Inc Details
2.8.2 Seattle Genetics Inc Major Business
2.8.3 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
2.8.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Seattle Genetics Inc Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Market Share
3.2.2 Top 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Market Share
3.2.3 Market Competition Trend
3.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Market Share by Type (2016-2021)
4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2016-2021)
5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2026)
6.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2026)
6.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
6.3.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2026)
6.3.2 United States Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
6.3.3 Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
6.3.4 Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2026)
7.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2026)
7.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
7.3.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2026)
7.3.2 Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
7.3.3 France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
7.3.5 Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
7.3.6 Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2026)
8.2 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2026)
8.3 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region
8.3.1 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2016-2026)
8.3.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8.3.3 Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8.3.4 South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8.3.5 India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
8.3.7 Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2026)
9.2 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2026)
9.3 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
9.3.1 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2026)
9.3.2 Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
9.3.3 Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2026)
10.2 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2026)
10.3 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country
10.3.1 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2026)
10.3.2 Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
10.3.4 UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) by Region (2016-2021)
Table 5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Plc Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Plc Major Business
Table 8. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 9. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 13. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Gilead Sciences Inc Corporate Information, Head Office, and Major Competitors
Table 15. Gilead Sciences Inc Major Business
Table 16. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 17. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Modus Therapeutics Holding AB Corporate Information, Head Office, and Major Competitors
Table 19. Modus Therapeutics Holding AB Major Business
Table 20. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 21. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 23. Novartis AG Major Business
Table 24. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 25. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. NuvOx Pharma LLC Corporate Information, Head Office, and Major Competitors
Table 27. NuvOx Pharma LLC Major Business
Table 28. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 29. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer Inc Major Business
Table 32. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 33. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Seattle Genetics Inc Corporate Information, Head Office, and Major Competitors
Table 35. Seattle Genetics Inc Major Business
Table 36. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Solutions
Table 37. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) by Players (2019-2021)
Table 39. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Players (2019-2021)
Table 40. Breakdown of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Head Office, Products and Services Provided
Table 42. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Mergers & Acquisitions in the Past Five Years
Table 43. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug New Entrants and Expansion Plans
Table 44. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) by Type (2016-2021)
Table 45. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2016-2021)
Table 46. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Forecast by Type (2021-2026)
Table 47. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021)
Table 48. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Forecast by Application (2021-2026)
Table 49. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Picture
Figure 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type in 2020
Figure 3. SGD-2083
Figure 4. Crizanlizumab
Figure 5. PF-04447943
Figure 6. NVX-508
Figure 7. Others
Figure 8. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application in 2020
Figure 9. Clinic Picture
Figure 10. Hospital Picture
Figure 11. Others Picture
Figure 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Region (2016-2026)
Figure 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Region in 2020
Figure 16. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
Figure 22. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
Figure 23. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Trends
Figure 24. AstraZeneca Plc Recent Developments and Future Plans
Figure 25. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 26. Gilead Sciences Inc Recent Developments and Future Plans
Figure 27. Modus Therapeutics Holding AB Recent Developments and Future Plans
Figure 28. Novartis AG Recent Developments and Future Plans
Figure 29. NuvOx Pharma LLC Recent Developments and Future Plans
Figure 30. Pfizer Inc Recent Developments and Future Plans
Figure 31. Seattle Genetics Inc Recent Developments and Future Plans
Figure 32. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Players in 2020
Figure 33. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share in 2020
Figure 35. Global Top 10 Players Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type in 2020
Figure 38. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share Forecast by Type (2021-2026)
Figure 39. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application in 2020
Figure 40. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share Forecast by Application (2021-2026)
Figure 41. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Type (2016-2026)
Figure 42. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Application (2016-2026)
Figure 43. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Country (2016-2026)
Figure 44. United States Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Type (2016-2026)
Figure 48. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Application (2016-2026)
Figure 49. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Country (2016-2026)
Figure 50. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Region (2016-2026)
Figure 58. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Type (2016-2026)
Figure 65. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Application (2016-2026)
Figure 66. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の鎌状赤血球症診断市場予測（～2024年）：企業別、地域別、種類・用途別 Scope of the Report: The global Sickle Cell Disease Diagnosis market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in Ch…- 鎌状赤血球症治療市場：世界及び中国市場分析・予測（～2024年） Sickle Cell Disease Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Sickle Cell Disease Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Sickle Cel…
- ゴーシェ病薬市場：世界及び中国市場分析・予測（～2024年） Gaucher Disease Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Gaucher Disease Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Gaucher Disease Drug manufac…
- ポンペ病治療薬市場：世界及び中国市場分析・予測（～2024年） Pompe Disease Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pompe Disease Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pompe Disease Drug manufacturers…
- シャーガス病治療薬市場：世界及び中国市場分析・予測（～2024年） Chagas Disease Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Chagas Disease Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Chagas Disease Drug manufactur…